•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
Janux Therapeutics (NASDAQ:JANX) and Zai Lab (NASDAQ:ZLAB) Head-To-Head Survey
Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
Here Are Monday’s Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino’s Pizza, Fortune Brands, Golar LNG, Jersey Mike’s Subs, Roku, and More
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
Here's Why You Should Add JANX Stock to Your Portfolio Now
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development